Funded Startups in Bedford
Across the 25 most recent funding entries shown, disclosed round sizes cluster mostly in the low-to-mid tens of millions, but one outlier stands out: Stoke…
Across the 25 most recent funding entries shown, disclosed round sizes cluster mostly in the low-to-mid tens of millions, but one outlier stands out: Stoke Therapeutics raised $125M on 2024-03-27, which dwarfs the next-largest disclosed amounts in the table (e.g., Soft Robotics at $26M on 2022-11-17 and Access Vascular at $20M on 2021-03-03). Most rounds are also dated tightly near the surface of the timeline: the latest row is NOVONIX on 2026-06-17, while the oldest shown dates back to Access Vascular on 2021-03-03.
City naming splits the dataset: “Bedford, Massachusetts” appears repeatedly (e.g., Predictive Healthcare 2026-06-16 for $250K; Rejoni 2026-06-16 for $25M; CranioSense 2025-12-17 for $6M), alongside “Bedford, Nova Scotia” (NOVONIX $15M on 2026-06-17; The Halifax Honey $20K on 2026-05-13; QuickFacts $2M on 2024-08-14) and “Bedford, Bedfordshire, United Kingdom” (e.g., Signify Research $8M on 2024-10-14; Real Bedford FC $5M on 2024-04-12). Stage and disclosure are also mixed: Series Unknown appears 20 times, with two explicitly “undisclosed” amounts (Sponza on 2026-02-03; Compedica on 2025-06-09) and one additional entry with undisclosed amount (Rhealth on 2025-01-14).
Most recent rounds
25 shownRelated listings
Frequently asked
What’s the largest disclosed round in this Bedford listing, and how does it compare with the next-largest disclosed rounds?
Stoke Therapeutics’ $125M on 2024-03-27 is the only disclosed round above $50M in the table. The next-largest disclosed amounts are materially smaller, including Soft Robotics at $26M on 2022-11-17 and CubicPV at $33M on 2023-06-13.
Are there clear concentration windows near the most recent dates, or is funding spread evenly across 2021–2026?
The list is front-loaded toward the end of the range: 2026 entries run from 2026-06-17 (NOVONIX, $15M) down through 2026-02-03 (Sponza, undisclosed). The oldest shown date is 2021-03-03 (Access Vascular, $20M), with no comparable clustering indicated by the later half alone.
Do specific Bedford geographies dominate, or are the “Bedford” entries evenly distributed across regions?
The name “Bedford” is split across countries/states, but Bedford, Massachusetts shows repeated entries tied to multiple AI and healthcare/biotech companies (e.g., Predictive Healthcare on 2026-06-16 for $250K; Rejoni on 2026-06-16 for $25M; Rhealth on 2025-01-14 with undisclosed amount). Bedford, Nova Scotia also reappears (NOVONIX $15M on 2026-06-17; QuickFacts $2M on 2024-08-14; The Halifax Honey $20K on 2026-05-13), and Bedford, Bedfordshire (UK) appears with multiple disclosed rounds such as Signify Research $8M on 2024-10-14.
What stage mix dominates, and how often are amounts disclosed versus undisclosed?
Series Unknown is the dominant stage label: 20 of 25 rows show “Series Unknown.” Disclosure also skews toward disclosed amounts, with three “undisclosed” amounts visible (Sponza on 2026-02-03; Compedica on 2025-06-09; Rhealth on 2025-01-14), while explicit stages like Seed (e.g., Zengines $9M on 2024-11-07) and Series B/C (Access Vascular $20M on 2021-03-03; Soft Robotics $26M on 2022-11-17) appear less frequently.
Which sectors appear most often in this list, and do any sectors align with outlier-sized rounds?
Biotechnology and Artificial Intelligence each recur across multiple entries (e.g., Biotechnology includes Rejoni $25M on 2026-06-16, Rapid Micro Biosystems $32M on 2026-05-19, CranioSense $6M on 2025-12-17; AI includes Predictive Healthcare $250K on 2026-06-16 and Zengines $9M on 2024-11-07). The largest outlier, Stoke Therapeutics at $125M on 2024-03-27, is categorized as Biotechnology, but the table does not show a comparably large AI or other-sector round near it.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.